Prospective Validation of the Prognostic Value of Long Non-coding MFI2-AS1 RNA in Localized Clear Cell Kidney Cancers

NCT04946266 | Unknown

• 1 other identifier: 7349
• Study Type: observational
• Target: 260
• Locations: 1 country
• Sites: 1

Brief Summary

An exploratory analysis of the expression of MFI2-AS1 will be performed at the plasma level with the objective of comparing this expression with tumor tissue. The objective would be to be able to use long non-coding RNA as a biomarker for diagnosis before tissue analysis and for patient follow-up. In addition, correlations will be made between tumor expression of MFI2-AS1 and genetic and immune alterations in tumors in order to better clarify the link between the expression of this long non-coding RNA and the characteristics of the tumor and of the tumor. tumor microenvironment.

Conditions

Kidney Cancer

Outcome Measures

Primary Outcomes (1)

• Expression of MFI2-AS1

  To assess the link between tumor expression of MFI2-AS1 in patients with localized clear cell kidney carcinoma and the occurrence of relapse

  36 month

Interventions

Surgical intervention PROCEDURE

Surgical intervention with collection of tissue material

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patient with localized kidney tumors

You may qualify if:

• Adult patient
• Localized kidney tumors\> T1a
• Patient having signed an informed consent
• Patient affiliated to a health insurance plan
• Subject having signed a consent form to participate in research and the constitution of a collection and genetic analyzes

You may not qualify if:

• Metastatic carcinoma from the outset
• Contraindication to performing a TAP CT with injection of contrast product
• Inability to provide informed information about the subject (subject in an emergency situation, difficulties in understanding, etc.)
• Subject under legal protection
• Subject under tutorship or curatorship
• Pregnancy
• Feeding with milk

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Les Hôpitaux Universitaires de Strasbourg

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Kidney Neoplasms

Interventions

Surgical Procedures, Operative

Condition Hierarchy (Ancestors)

Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Kidney Diseases; Urologic Diseases; Male Urogenital Diseases

Study Officials

• TRICARD Thibault

  les Hôpitaux Universitaires de Strasbourg

  PRINCIPAL INVESTIGATOR

Central Study Contacts

TRICARD Thibault

CONTACT

+ 33 3.69.55.10.55; Thibaut.tricard@chru-strasbourg.fr

MALOUF Gabriel

CONTACT

+33 3.88.11.51.41; Gabriel.malouf@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 22, 2021
• First Posted: June 30, 2021
• Study Start: December 1, 2021
• Primary Completion: December 1, 2021
• Study Completion: December 1, 2024
• Last Updated: January 5, 2022

Record last verified: 2021-12

Locations

FR (1)